OOIR: Observatory of International Research

Papers

(The H4-Index of Neurology is 80. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Neurologic manifestations in hospitalized patients with COVID-19	586
Miller Fisher syndrome and polyneuritis cranialis in COVID-19	567
Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions	345
Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19	294
International Consensus Guidance for Management of Myasthenia Gravis	270
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis	262
Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy	254
Twenty-seven-year time trends in dementia incidence in Europe and the United States	226
COVID-19 presenting with ophthalmoparesis from cranial nerve palsy	225
COVID-19 and neuromuscular disorders	214
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy	208
A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City	197
Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid	186
Early postmortem brain MRI findings in COVID-19 non-survivors	185
Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy	171
Neurologic and neuroimaging findings in patients with COVID-19	170
Global prevalence and burden of HIV-associated neurocognitive disorder	169
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis	161
Frequency of Neurologic Manifestations in COVID-19	155
National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome	153
Neurologic complications of coronavirus infections	147
Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic	145
Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder	141
Different phenotypes in dermatomyositis associated with anti-MDA5 antibody	141
Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI	138

Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection	135
Neurofilament light as a biomarker in traumatic brain injury	134
COVID-19 is catalyzing the adoption of teleneurology	128
Incidence and Prevalence of Drug-Resistant Epilepsy	127
Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies	126
Healthy lifestyle and the risk of Alzheimer dementia	125
Global, Regional, and National Burden of Ischemic Stroke, 1990–2019	124
New onset neurologic events in people with COVID-19 in 3 regions in China	121
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS	120
Long-Haul COVID	120
Bilateral transient olfactory bulb edema during COVID-19–related anosmia	119
Practice advisory update summary: Patent foramen ovale and secondary stroke prevention	118
Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures	113
Neurologic Adverse Events of Immune Checkpoint Inhibitors	112
Keeping people with epilepsy safe during the COVID-19 pandemic	112
Rapid implementation of virtual neurology in response to the COVID-19 pandemic	108
Secondary Progressive Multiple Sclerosis	108
Neurologic manifestations in an infant with COVID-19	104
APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies	103
Analyzing 2,589 child neurology telehealth encounters necessitated by the COVID-19 pandemic	103
Serum neurofilament light as a biomarker in progressive multiple sclerosis	103
Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19	101
Criteria for defining interictal epileptiform discharges in EEG	101
Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline	101
Generalized myoclonus in COVID-19	100
Brain arteriovenous malformations	98
Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease	98
Long-term safety, tolerability, and efficacy of fremanezumab in migraine	96
ATN classification and clinical progression in subjective cognitive decline	96
Stroke risk, phenotypes, and death in COVID-19	96
Natural History, Phenotypic Spectrum, and Discriminative Features of Multisystemic RFC1 Disease	96
Neurologic autoimmunity and immune checkpoint inhibitors	95
In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease	95
Association of epileptiform abnormalities and seizures in Alzheimer disease	94
Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies	92
Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis	91
Determination of death by neurologic criteria around the world	91
Sex-driven modifiers of Alzheimer risk	90
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques	89
Initial high-efficacy disease-modifying therapy in multiple sclerosis	87
Five years of ocrelizumab in relapsing multiple sclerosis	87
Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke	87
Loss of smell in patients with COVID-19	87
Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy	87
Intracranial hemodynamic relationships in patients with cerebral small vessel disease	86
Global Impact of COVID-19 on Stroke Care and IV Thrombolysis	85
Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease	83
Worldwide Incidence and Prevalence of Neuromyelitis Optica	82
Incidence and case fatality rate of COVID-19 in patients with active epilepsy	82
Exosomal neurofilament light	82

Guillain-Barré Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial	82
Thrombus NET content is associated with clinical outcome in stroke and myocardial infarction	82
Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease	82
Cranial neuropathies and COVID-19	81
Tobacco smoking and the risk of Parkinson disease	81
Probiotics for Constipation in Parkinson Disease	80
Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders	80